Colin Bristow
Stock Analyst at UBS
(1.91)
# 3,226
Out of 5,044 analysts
103
Total ratings
36.67%
Success rate
-6.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $117.88 | -4.99% | 4 | Aug 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $582 → $553 | $422.39 | +30.92% | 15 | Aug 5, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $67.49 | +18.54% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $3.97 | +25.94% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $1.54 | -35.06% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $21.98 | -22.66% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $292.09 | +9.21% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $2.29 | +74.67% | 4 | Mar 28, 2025 | |
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $7.81 | -10.37% | 2 | Feb 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $24.50 | +14.29% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $87.03 | +37.88% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $149.13 | +35.45% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $2.18 | +633.94% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $654.48 | +67.92% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $24.22 | +589.51% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $820.10 | -48.79% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $7.96 | -74.87% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.04 | +492.11% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $227.54 | -35.84% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $42.82 | +75.15% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $2.58 | +907.75% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.60 | +60.71% | 1 | Aug 23, 2021 |
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $117.88
Upside: -4.99%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Buy
Price Target: $582 → $553
Current: $422.39
Upside: +30.92%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $67.49
Upside: +18.54%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $3.97
Upside: +25.94%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $1.54
Upside: -35.06%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $21.98
Upside: -22.66%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $292.09
Upside: +9.21%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $2.29
Upside: +74.67%
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $7.81
Upside: -10.37%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $24.50
Upside: +14.29%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $87.03
Upside: +37.88%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $149.13
Upside: +35.45%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $2.18
Upside: +633.94%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $654.48
Upside: +67.92%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $24.22
Upside: +589.51%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $820.10
Upside: -48.79%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $7.96
Upside: -74.87%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $3.04
Upside: +492.11%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $227.54
Upside: -35.84%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $42.82
Upside: +75.15%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $2.58
Upside: +907.75%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $5.60
Upside: +60.71%